Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.